QQ客服 官方微博 反馈留言

	Sorafenib treatment and safety profile in Child Pugh B patients characterized in first interim results of GIDEON (Global Investigation of Therapeutic Decisions In Hepatocellular Carcinoma And Of Its Treatment With Sorafenib)
	Lencioni R., Lim H.Y., Sta藲l P., Marrero J.A., Kudo M., Venook A., Strauss U.P., Ye S.-L.
刊名	Onkologie
	2011
ISSN号	0378-584X
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4929217
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Lencioni R., Lim H.Y., Sta藲l P., Marrero J.A., Kudo M., Venook A., Strauss U.P., Ye S.-L.. Sorafenib treatment and safety profile in Child Pugh B patients characterized in first interim results of GIDEON (Global Investigation of Therapeutic Decisions In Hepatocellular Carcinoma And Of Its Treatment With Sorafenib)[J]. Onkologie,2011.
APA	Lencioni R., Lim H.Y., Sta藲l P., Marrero J.A., Kudo M., Venook A., Strauss U.P., Ye S.-L..(2011).Sorafenib treatment and safety profile in Child Pugh B patients characterized in first interim results of GIDEON (Global Investigation of Therapeutic Decisions In Hepatocellular Carcinoma And Of Its Treatment With Sorafenib).Onkologie.
MLA	Lencioni R., Lim H.Y., Sta藲l P., Marrero J.A., Kudo M., Venook A., Strauss U.P., Ye S.-L.."Sorafenib treatment and safety profile in Child Pugh B patients characterized in first interim results of GIDEON (Global Investigation of Therapeutic Decisions In Hepatocellular Carcinoma And Of Its Treatment With Sorafenib)".Onkologie (2011).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。